Shire announced that the FDA has approved Intuniv (guanfacine extended-release tablets) for use as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6–17 years as part of a total treatment program. The approval is based on results from a nine-week, multicenter, double-blind, randomized placebo-controlled study in children and adolescents with ADHD given Intuniv in combination with a stimulant.

Intuniv, a nonstimulant, selective α2A-agonist, is already indicated as monotherapy for the treatment of ADHD in children and adolescents 6–17 years old.

For more information call (800) 828-2088 or visit